These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36584930)

  • 1. Coping with the ESKAPE pathogens: Evolving strategies, challenges and future prospects.
    Aloke C; Achilonu I
    Microb Pathog; 2023 Feb; 175():105963. PubMed ID: 36584930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.
    Mulani MS; Kamble EE; Kumkar SN; Tawre MS; Pardesi KR
    Front Microbiol; 2019; 10():539. PubMed ID: 30988669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foodborne ESKAPE Biofilms and Antimicrobial Resistance: lessons Learned from Clinical Isolates.
    Patil A; Banerji R; Kanojiya P; Saroj SD
    Pathog Glob Health; 2021 Sep; 115(6):339-356. PubMed ID: 33851566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
    Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
    J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial Resistance in ESKAPE Pathogens.
    De Oliveira DMP; Forde BM; Kidd TJ; Harris PNA; Schembri MA; Beatson SA; Paterson DL; Walker MJ
    Clin Microbiol Rev; 2020 Jun; 33(3):. PubMed ID: 32404435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update.
    Bakhtiyari N; Farajnia S; Ghasemali S; Farajnia S; Pormohammad A; Saeidvafa S
    Infect Disord Drug Targets; 2024; 24(6):e260124226226. PubMed ID: 38284691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy for ESKAPE pathogens: An emerging approach to combat antimicrobial resistance (AMR).
    Mathur A; Parihar AS; Modi S; Kalra A
    Microb Pathog; 2023 Oct; 183():106307. PubMed ID: 37604213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.
    Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q
    ACS Infect Dis; 2024 Jul; 10(7):2336-2355. PubMed ID: 38866389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria.
    Cavallazzi Sebold B; Li J; Ni G; Fu Q; Li H; Liu X; Wang T
    BioDrugs; 2023 Sep; 37(5):607-623. PubMed ID: 37300748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of indole hybrids, dimers, and trimers against drug-resistant ESKAPE pathogens.
    Qiongxian Y; Jun D; Zhenfeng Z; Tongyou L; Zhicong T; Zhenyou T
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400295. PubMed ID: 38924571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.
    Euler CW; Raz A; Hernandez A; Serrano A; Xu S; Andersson M; Zou G; Zhang Y; Fischetti VA; Li J
    Antimicrob Agents Chemother; 2023 May; 67(5):e0151922. PubMed ID: 37098944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens.
    Zohra T; Numan M; Ikram A; Salman M; Khan T; Din M; Salman M; Farooq A; Amir A; Ali M
    Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acinetobacter baumannii: Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline.
    Dehbanipour R; Ghalavand Z
    J Clin Pharm Ther; 2022 Nov; 47(11):1875-1884. PubMed ID: 36200470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
    Tiwari V; Meena K; Tiwari M
    Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternatives for the treatment of infections caused by ESKAPE pathogens.
    da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
    J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photoinactivation of ESKAPE pathogens: overview of novel therapeutic strategy.
    Nakonieczna J; Wozniak A; Pieranski M; Rapacka-Zdonczyk A; Ogonowska P; Grinholc M
    Future Med Chem; 2019 Mar; 11(5):443-461. PubMed ID: 30901231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriophages for ESKAPE: role in pathogenicity and measures of control.
    Patil A; Banerji R; Kanojiya P; Koratkar S; Saroj S
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):845-865. PubMed ID: 33261536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
    Santajit S; Indrawattana N
    Biomed Res Int; 2016; 2016():2475067. PubMed ID: 27274985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
    Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
    Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health.
    Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W
    Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.